Halozyme Therapeutics, Inc. filings document the company's drug-delivery business, royalty-based collaboration model, governance actions and capital-market disclosures. 8-K reports cover financial results and guidance, executive officer appointments and compensation arrangements, bylaw amendments, and annual meeting voting results.
Proxy materials describe board elections, executive compensation, equity awards, auditor ratification and stockholder voting mechanics. Filings also provide formal disclosure around ENHANZE, Hypercon and Surf Bio technology portfolio updates, partnered commercial products, and acquisition-related operating updates when reported by the company.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton received equity compensation awards on May 5, 2026. She was granted 6,796 restricted stock units (RSUs), each representing one share of common stock, and a stock option for 6,040 shares at an exercise price of $65.87 per share.
Both the RSU grant and the option grant will vest in full on the earlier of May 5, 2027 or the date of the company’s next annual meeting of stockholders. Following the RSU award, Connaughton directly holds 45,294 shares of common stock.
Halozyme Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on May 5, 2026. Of 118,474,300 common shares outstanding as of the record date, 104,138,244 shares were represented, meaning a large majority of shareholders participated.
Stockholders elected Bernadette Connaughton and Matthew L. Posard as Class I directors for three-year terms, with each receiving more than a majority of the outstanding shares. They also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton sold 1,625 shares of common stock in an open-market transaction at $63.48 per share. After this sale, she directly holds 38,498 shares. The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance.
Halozyme Therapeutics Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 6,173,547 shares of Common Stock, representing 5.21% of the class as reported for the period ending 03/31/2026. The filing shows sole dispositive power of 6,173,547 shares and sole voting power of 902,329 shares. The filing is signed by Ashley Grim on 04/30/2026.
Halozyme Therapeutics Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 6,173,547 shares of Common Stock, representing 5.21% of the class as reported for the period ending 03/31/2026. The filing shows sole dispositive power of 6,173,547 shares and sole voting power of 902,329 shares. The filing is signed by Ashley Grim on 04/30/2026.
Halozyme Therapeutics has appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026, succeeding interim CFO David Ramsay, who will move to an advisory role during a brief transition. Snellgrove brings more than 30 years of finance leadership, most recently serving as Vice President, Investor Relations and previously as CFO of Johnson & Johnson’s Pharmaceuticals sector.
His compensation includes a $670,000 annual salary, a target bonus equal to 50% of salary (prorated for 2026), and a minimum $4,000,000 long-term incentive award in 2027. Upon joining, he will receive equity awards with a total grant date value of $7,200,000, split between $3,200,000 in restricted stock units that vest over three years and $4,000,000 in stock options vesting over four years under the 2021 Stock Plan, plus a $350,000 sign-on cash bonus subject to partial repayment if he leaves or is terminated for misconduct within 24 months.
Halozyme Therapeutics has appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026, succeeding interim CFO David Ramsay, who will move to an advisory role during a brief transition. Snellgrove brings more than 30 years of finance leadership, most recently serving as Vice President, Investor Relations and previously as CFO of Johnson & Johnson’s Pharmaceuticals sector.
His compensation includes a $670,000 annual salary, a target bonus equal to 50% of salary (prorated for 2026), and a minimum $4,000,000 long-term incentive award in 2027. Upon joining, he will receive equity awards with a total grant date value of $7,200,000, split between $3,200,000 in restricted stock units that vest over three years and $4,000,000 in stock options vesting over four years under the 2021 Stock Plan, plus a $350,000 sign-on cash bonus subject to partial repayment if he leaves or is terminated for misconduct within 24 months.
Halozyme Therapeutics, Inc. has amended its Bylaws following approval by the Board of Directors on April 22, 2026. Directors may now be removed at any time, with or without cause, by holders of a majority of shares entitled to vote in director elections.
The amendment also clarifies that stockholder actions that would otherwise be taken at an annual or special meeting may not be taken without a meeting, aligning the Bylaws with Article FIFTH of the Company’s Certificate of Incorporation. The full amended Bylaws are provided as Exhibit 3.1.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley exercised stock options for 10,000 shares of common stock at an exercise price of $12.070 per share on April 6, 2026. The options were part of a grant dated February 22, 2017 with a ten-year term.
On the same date, she sold a total of 10,000 common shares in open-market transactions at weighted average prices of $63.139 and $64.015 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she directly holds 767,780 common shares.
RAMSAY DAVID A reported acquisition or exercise transactions in this Form 4 filing.
HALOZYME THERAPEUTICS, INC. reported that interim CFO David A. Ramsay received a grant of 10,000 Restricted Stock Units tied to the company’s common stock. These RSUs were awarded as compensation rather than through an open-market purchase or sale.
The award vests in full on June 30, 2026, provided he remains employed through that date. After vesting, the shares are subject to a one-year holding period, meaning he must continue to hold the resulting shares for an additional year. Following this grant, his directly held RSU-related position from this award is 10,000 units.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported an exercise-and-sell transaction in company stock. On April 1–2, she exercised options to acquire a total of 40,000 shares of common stock at an exercise price of $12.0700 per share, from options with a ten-year term expiring in February 2027.
Over the same two days, she sold 40,000 shares of common stock in open-market trades at per-share prices including $65.3580, $65.7140, $64.0630 and $64.8870. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, she directly owned 767,780 shares of Halozyme common stock.